PPARA and steatosis: Compared with single or dual PPAR agonists, the pan-PPAR agonist lanifibranor decreased at least 2 points in the activity part of steatosis, activity, and fibrosis scoring system in a phase 2b trial, but increased the risk of diarrhea, nausea, etc. [200].